Overview
- This week Boehringer Ingelheim confirmed it will stop €900 million of planned German investments for 2027–2030 and Eli Lilly said it will halve the remaining spend on its Alzey plant, reducing the project’s scale and job plans.
- Both companies pointed to the federal GKV savings draft that increases manufacturer rebate obligations as a central cause, saying higher, uncertain rebates make long‑cycle pharmaceutical investments harder to plan.
- Eli Lilly expects the Alzey facility to open in 2027 with smaller capacity and about 500 direct jobs instead of the initially planned 1,000, while Boehringer says routine maintenance spending and current jobs are safe even as new infrastructure projects are shelved.
- The federal health ministry called the firms’ choices regrettable but defended the reform as necessary to stabilise statutory insurance finances, and Rheinland‑Pfalz authorities have opened talks with the companies to try to limit local fallout.
- Analysts and industry groups warn the moves may redirect capital and R&D to the United States and Asia, noting US policy incentives that tie market access or tariff relief to local investment and the Bundestag timetable for the GKV bill in June could affect further corporate decisions.